Feraheme (ferumoxytol injection) / Azurity Pharma - LARVOL DELTA

Bleeding Into Injury: Ferumoxytol-CMR-Defined Intramyocardial Hemorrhage Identifies a Multi-Domain High-Risk Phenotype After Reperfused STEMI (AHA 2026) - No abstract available

Hematological Disorders

Hearts on Fire: Targeting Inflammation in Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) - P1 | N=70 | Recruiting | Sponsor: University of Florida

New P1 trial • Cardiovascular • Heart Failure • Inflammation

Nanozymes for periodontal biofilm-associated challenges: mechanisms, platforms, and translational perspectives. (PubMed, Front Bioeng Biotechnol) - "These include Ru-C3N4 single-atom nanozymes (tested in otitis media models), AgAu-CeO2 heterojunction nanozymes with probiotics, ferumoxytol (tested in apical periodontitis), mitochondria-targeted ferritin nanozymes, and Ru@COF nanozymes. Despite encouraging preclinical evidence, challenges in long-term biosafety, metal-ion accumulation, and clinical translation persist. Future research should prioritize standardized safety evaluation, biodegradable designs, and clinical validation to translate nanozyme-based therapies from bench to bedside."

Journal • Review • Dental Disorders • Infectious Disease • Inflammation • Otorhinolaryngology • Periodontitis • CAT

One Minute to Collapse: Hyperacute Ferumoxytol Hypersensitivity in an Anesthesia-Led Perioperative Clinic (ASA 2026) - "Immediate response included infusion cessation and activation of a transfusion reaction protocol with access to a reaction kit, enabling intramuscular epinephrine, bag-mask ventilation, and albuterol. The patient stabilized and was transferred via EMS. Allergy consultation determined the presentation was consistent with a Grade 3 hypersensitivity reaction."

Colon Cancer • Colorectal Cancer • Immunology • Solid Tumor

Fast and robust T1 mapping based on a 3D dual-echo UTE sequence (PETALUTE) for superparamagnetic iron oxide nanoparticle (SPION) biodistribution assessment. (PubMed, Med Phys) - "The proposed PETALUTE-based T1 mapping enables fast and positive-contrast ferumoxytol imaging with higher spatial coverage and more stable measurements across a wider concentration range than conventional RARE-VTR T1 mapping."

Journal • Breast Cancer • Oncology • Solid Tumor

Translational Progress of Inorganic Nanotheranostic Platforms for Gynecologic Malignancies: A Narrative Review of Endometrial, Ovarian, and Cervical Cancer Focusing on Fertility Preservation, Biosafety, and Industrial Translation. (PubMed, Int J Nanomedicine) - "Clinically, carbon nanoparticle suspensions have direct evidence for sentinel lymph node mapping in endometrial cancer, whereas the strongest ovarian cancer precedents for locoregional and nanomedicine delivery remain non-inorganic, including hyperthermic intraperitoneal chemotherapy and pegylated liposomal doxorubicin...We identified no inorganic nanomedicine currently approved specifically for a gynecologic malignancy; ferumoxytol is approved as an intravenous iron replacement product, and AuroLase gold nanoshells remain investigational, with no gynecologic trial identified...EC- and OC-derived organoids provide increasingly mature disease models that could support nanotherapeutic screening, but direct nanomedicine validation remains limited, while AI-assisted design is constrained by small heterogeneous datasets and limited external validation. Future progress will depend on reproductive-safety endpoints, appropriately validated PDO models, standardized manufacturing..."

Journal • Review • Cervical Cancer • Endometrial Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Systematic Review and Meta-Analysis of Hypersensitivity Reactions after High-dose Intravenous Iron. (PubMed, Blood Adv) - "We synthesized the available data on serious or severe HSR incidence for ferric derisomaltose (FDI), ferric carboxymaltose (FCM), and ferumoxytol (FER), as treatments for iron deficiency anemia (IDA)...SUCRA plots showed that the likelihood of FDI having the lowest serious or severe HSR incidence was 91.4% (FCM: 4.5%; FER: 4.2%). This meta-analysis of data from RCTs, including 11,268 patients, represents a comprehensive analysis of serious or severe HSRs among the available high-dose IV iron formulations, detailing an important facet of formulations' safety profiles."

Journal • Retrospective data • Hematological Disorders • Immunology

Editorial for "Measurements of Liver and Bone Marrow Proton Density Fat Fraction in the Setting of Ferumoxytol-Enhanced MRI". (PubMed, J Magn Reson Imaging) - No abstract available

Journal

Development of a 24-channel 3T phased-array coil for fMRI in awake monkeys: Mitigating spatiotemporal artifacts in ferumoxytol-weighted functional connectivity estimation. (PubMed, Imaging Neurosci (Camb)) - "At the group level, we identified dense functional networks with spatial features homologous to those observed in humans. The developed RF receive coil, image acquisition protocols, and data analysis pipelines are publicly available, providing the broader scientific community with tools to leverage these advances for further research."

Journal • Anesthesia

Exploring the Diagnostic Utility of Ferumoxytol for Brachial Plexus MR Neurography. (PubMed, Radiology) - "Conclusion Ferumoxytol improved vascular suppression compared with noncontrast and gadolinium-enhanced 3D short-tau inversion-recovery fast spin-echo sequences in brachial plexus MRN, enhancing the conspicuity of several nerve branches versus noncontrast scans, with similar detection of abnormal nerve findings."

Journal • Genetic Disorders • Musculoskeletal Diseases • Turners Syndrome • Vascular Neurology

Nanozymes in Endodontics (clinicaltrials.gov) - P4 | N=72 | Enrolling by invitation | Sponsor: University of Pennsylvania | Trial primary completion date: Jun 2027 ➔ Jun 2028 | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Trial primary completion date • Dental Disorders • Gastrointestinal Disorder • Infectious Disease • Periodontitis

Redox-modulating metallic nanoparticles: mechanistic insights into pharmacological activity and cellular therapeutics. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Although agents such as Ferumoxytol and Hensify have reached clinical application, challenges regarding long-term toxicity, immunogenicity, and systemic clearance remain. Future directions in this field emphasize the development of stimuli-responsive nanoplatforms for scientifically controlled and reproducible cargo release and the integration of computational tools to predict biological interactions. These advances are expected to provide deeper mechanistic insights into pharmacological activity at the nano-bio interface."

Journal • Review • Alzheimer's Disease • Cardiovascular • CNS Disorders • Infectious Disease • Movement Disorders • Oncology • Parkinson's Disease • CAT

Enhanced Glioblastoma Targeting and Penetration: Extracellular Matrix Remodeling by Collagenase-Functionalized Ferumoxytol Nanoparticles. (PubMed, Nano Lett) - "TNP-collagenase combined with temozolomide (TMZ) induced significant tumor regression compared with PBS + TMZ and ferumoxytol + TMZ. Histological analyses confirmed degradation of perivascular collagen-IV and improved intratumoral distribution of therapeutics. These results establish enzyme-activated ECM remodeling as a nanomedicine strategy to enhance drug delivery and therapeutic efficacy in GBM while enabling noninvasive imaging of treatment response."

Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • CTSB

Interappointment pain reduction with three intracanal medicaments: A randomized clinical trial. (PubMed, J Conserv Dent Endod) - "Ferumoxytol emerges as a promising intracanal medicament with targeted biofilm disruption and reduced drawbacks compared to conventional agents. Its clinical potential in minimizing interappointment pain highlights its relevance as an alternative to calcium hydroxide and mTAP."

Clinical • Journal • Pain • MTAP

Commentary on Ferumoxytol and Beyond: Navigating the Shift Away From GBCAs in Neuro-Oncology. (PubMed, J Magn Reson Imaging) - No abstract available

Journal • Oncology

Ferumoxytol dose optimization for three-dimensional whole-heart magnetic resonance imaging in patients with congenital heart disease. (PubMed, Pediatr Radiol) - "Ferumoxytol-enhanced 3D WH imaging provides diagnostic-quality assessment across 1-3 mg/kg dosing. Dose-dependent TI shortening follows a nonlinear, saturating pattern, supporting optimized low-dose protocols."

Journal • Cardiovascular • Heart Failure • Pediatrics

Hypophosphatemia in Patients Receiving Intravenous Iron Supplementation for Iron-Deficiency Anemia: A Narrative Review. (PubMed, J Clin Med) - "In clinical trials, rates of hypophosphatemia were significantly higher in patients receiving FCM compared with other IV iron formulations, such as ferric derisomaltose and ferumoxytol. Treatment guidelines recommend monitoring serum phosphate levels in patients receiving FCM who are at risk for low phosphate or who require repeat infusions, and alternative iron formulations should be considered in at-risk patients. This narrative review summarizes current evidence regarding IV iron-induced hypophosphatemia in individuals with IDA and examines the underlying pathophysiology and clinical evidence for IV iron-induced hypophosphatemia, particularly with FCM, the populations most at risk, and the clinical consequences of persistent hypophosphatemia."

Journal • Review • Anemia • Fatigue • Hematological Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Pain • Renal Disease • FGF23

Ferumoxytol enhances NF-κB-responsive GBA-targeted ferroptosis gene therapy in acute myeloid leukemia. (PubMed, J Nanobiotechnology) - "The combination significantly prolonged survival in AML-bearing mice and produced no notable toxicity to major organs, hematologic parameters, or liver and kidney function tests. In summary, combination therapy with FeNPs and miGBA achieves potent anti-AML efficacy with favorable in vivo safety, and has potential for clinical development."

Journal • Acute Myelogenous Leukemia • Gene Therapies • Hematological Disorders • Hematological Malignancies • Leukemia • Lysosomal Storage Diseases • Metabolic Disorders • Oncology • Rare Diseases • NFKB1

Thermal and imaging effects of Feraheme in MR-guided focused ultrasound: a phantom study. (PubMed, Phys Med Biol) - "All NMR measurements demonstrated stable, linear PRF temperature dependence (R² = 0.996-0.999), with PRF coefficients (between -0.0074 and -0.0082 ppm/°C). The resulting thermometry bias was small and predictable (+0.67 and +1.73 per 20 °C at 3.0 T for 0.25 and 0.5 mM). Significance These findings demonstrate that MR thermometry remains feasible at moderate Feraheme concentrations and support its potential use to enhance visualization of critical vasculature near targeted tissues during MRgFUS.&#xD."

Journal • Oncology

Transient blood-brain barrier opening by focused ultrasound enhances ferumoxytol accumulation in glioblastoma. (PubMed, Mater Today Bio) - "Histopathological evaluation of H&E-stained normal brain and tumor sections showed no significant FUS-associated increase in detectable acute structural tissue damage. Our findings establish a quantitative and clinically translatable framework for spatially controlled FUS-enhanced delivery of clinically relevant nanoparticle formulations to brain tumors, advancing targeted delivery strategies for neuro-oncologic applications."

Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

DIVI: Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: University of Washington | Trial primary completion date: Oct 2026 ➔ Jan 2027

Trial primary completion date • Anemia • Hematological Disorders

Ferumoxytol triggers cancer ferroptosis via an NF-κB-driven IRONKILL mechanism. (PubMed, Cancer Biol Med) - No abstract available

Journal • Oncology

Intravenous Ferumoxytol Compared With Oral Ferrous Sulfate for Iron Deficiency Anemia in Pregnancy: A Randomized Controlled Trial. (PubMed, Obstet Gynecol) - P3 | "Treatment of IDA during pregnancy with IV ferumoxytol improved hemoglobin at delivery and reduced the prevalence of anemia to a greater extent than oral ferrous sulfate."

Clinical • Journal • Anemia • Hematological Disorders

A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects (clinicaltrials.gov) - P3 | N=75 | Recruiting | Sponsor: AMAG Pharmaceuticals, Inc. | Trial completion date: Oct 2025 ➔ Oct 2026 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Anemia • Hematological Disorders • Pediatrics

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD) (clinicaltrials.gov) - P3 | N=129 | Recruiting | Sponsor: AMAG Pharmaceuticals, Inc. | Trial completion date: Aug 2024 ➔ Aug 2026 | Trial primary completion date: Aug 2024 ➔ Aug 2026

Trial completion date • Trial primary completion date • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Pediatrics • Renal Disease